MedTrace Logo

Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients

NCT02147600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2022-12-23

No results posted yet for this study

Summary

The main goal of this study is to determine optimal cut-off values of adalimumab trough levels corresponding to good clinical response. Determination of these values is necessary to compose a therapeutic algorithm, in which the dosing schedule can be adjusted according to serum trough levels of adalimumab and AAA (anti-adalimumab antibodies). A secondary objective of this study is to further detect and quantify AAA and to correlate them with adalimumab and clinical response in a real life setting cohort of psoriatic patients.

Conditions

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Jo Lambert, Prof.Dr. · Ghent University, Dpt. of Dermatology

  • Emma Coussens · Ghent University, Dpt. of Dermatology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-09
Primary Completion
2014-04-10
Completion
2014-04-10

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147600 on ClinicalTrials.gov